Intralesional Cidofovir: A Systematic Review of Administration Protocols and Long-term Recurrence Rates in Adult and Juvenile Recurrent Respiratory Papillomatosis.

OBJECTIVE: This is a systematic review aimed to explore Cidofovir administration protocols, recurrence rates, and long-term effectiveness for severe cases of recurrent respiratory papillomatosis (RRP). The primary goal was to identify current practices, determine the preferred protocol, and assess the adjuvant therapy's ability to prevent long-term papilloma recurrence in juvenile and adult-onset disease. METHODS: The following databases were searched: Pubmed, Google Scholar (pages 1-10), EMBASE, Scopus, ISI (clarivate), Cochrane Library, and Journal Storage from 1996 to June 2022. Articles that reported the use of intralesional Cidofovir in RRP and reported remission/recurrence rates with follow-up were included in the review. The systematic review was registered through PROSPERO and contains the detailed protocol for the conduction of the review. RESULTS: A total of 389 records were identified, 126 titles and abstracts screened, 45 studies fully read, and 30 studies met the inclusion criteria. Two hundred and fourteen adult-onset RRP (AORRP) and 126 juvenile-onset RRP (JORRP) cases were treated with Cidofovir across the included studies. There was no universal protocol for administering Cidofovir, with variations in concentration, treatment period, number and interval of injections, and follow-up duration. Most lesions showed human papilloma virus types 6 and 11. Recurrence rates varied, and other outcomes reported included remission rates, lesion reduction, surgical intervals, and side effects. Some studies demonstrated significant improvements in disease severity and extended intervals between recurrences after Cidofovir administration. CONCLUSIONS: The analysis of 30 studies reveals the need for greater consistency in reporting treatment parameters and outcomes. The use of recurrence-free period as an outcome measure and the potential benefits of a concentration of 7.5 mg/mL are identified. Additionally, the importance of viral typing within papilloma lesions is emphasized. To further enhance understanding and establish optimal protocols, future research should focus on uniform reporting, including severity, dosage, interval, treatment duration, functional outcome, and related procedures. SYSTEMATIC REVIEW REGISTRATION: PROSPERO CRD42022299549.

Postoperative Voice Surgical Outcomes in Professional Singers vs Non-Singers.

OBJECTIVES: Professional singers often are described as vocal athletes, and just as professional athletes get injured, injuries to professional singers can occur during practice and performances. In other fields of medicine, research has shown that competitive sports athletes recover more quickly after orthopedic surgical procedures compared to non-athletes. The purpose of this study was to determine whether similar differences occur with voice patients by comparing voice surgical outcomes between professional singers and non-singers. METHODS: A retrospective cohort study was conducted that included a consecutive sample of 194 adult subjects who underwent voice surgical procedures in the operating room. All surgeries were performed by the same surgeon, the senior author of this study (RTS). Data were reviewed for patients with medical records between January 1, 2010 to February 1, 2022. Subjects who reported receiving income from singing or reported studying voice at a collegiate level or higher were classified as professional singers. Subjects reporting careers in all other professions, including unpaid avocational singers or singers without formal training, were assigned to the non-singer control group. The data were analyzed using SPSS statistical software. Statistical significance was determined using independent samples t test for continuous variables and Fisher's exact test or binary logistic regression for binary outcomes. RESULTS: There were 194 subjects included in this study (43.81% male/56.19% female). The average age was 42.60 ± 15.17. Ninety subjects were professional singers and 104 were non-singers. Revision of surgical plan was significantly different for professional singers compared to non-singers (14.44% versus 0%, P < 0.001). The rate of postoperative complications did not differ significantly between the singer and non-singer groups, even when adjusting for other factors. Professional singers presented with slightly more severe vocal fold hemorrhages on the first postoperative visit compared to non-singers (1.73 ± 0.73 versus 1.32 ± 0.65, P = 0.003), but there was no difference by the second visit. Following surgery, professional singers adhered to a longer duration of voice rest. However, both groups participated equally in voice therapy postoperatively. CONCLUSIONS: No differences were found in operative complications between professional singers and non-singers. This study describes outcomes and considerations in patient care for professional singers. It also provides insight into potentially modifiable factors, such as voice rest, that could impact patient care postoperatively.

Surgical Outcome of Low-Power-Density Blue Laser for Vascular Lesions of the Vocal Fold.

Photoangiolytic lasers such as the 532-nm potassium-titanyl-phosphate (KTP) and the novel 445-nm blue laser (introduced into the United States in 2020) are absorbed selectively by hemoglobin, permitting targeted ablation of vascular structures such as vascular malformations of the vocal fold (VF). Previously, we reported the high rate of success of KTP laser photocoagulation for VF vascular lesions. Compared with other photoangiolytic lasers, blue laser has the highest absorption in hemoglobin, and therefore it can be operated at lower power densities to minimize thermal injury to adjacent tissue. OBJECTIVE: The purpose of this study was to determine the efficacy and safety of blue laser for treatment of VF vascular lesions using low power densities, and to compare outcomes of blue laser with those of KTP laser. METHODS: Adult voice patients who underwent blue laser treatment of VF vascular lesions in the operating room at the lowest power densities that appeared clinically to cause the effect desired were included in this retrospective study. Baseline lesion characteristics and postoperative outcomes were assessed with a model that we had described previously. Postoperative outcomes were compared to those of previously reported KTP laser. RESULTS: Thirty-one subjects (54 VFs treated) underwent blue laser vaporization of VF vascular lesions (average age was 40.63 ± 17.51). Data were compared to those of 66 subjects (100 VFs) who had undergone KTP laser vaporization of VF vascular lesions. There were no significant differences in subject demographics, past medical or surgical history, or preoperative location or severity of vascular lesions. Surgical success for blue laser at the low power densities used was 3.74 ± 0.50, 3.55 ± 0.94, 3.90 ± 0.94, and 3.70 ± 1.11 (out of 5) at postoperative visits 1-4, respectively. Surgical objective score was significantly greater following KTP laser at every postoperative visit. Treatment with KTP laser resulted in significantly greater generalized postoperative edema, and blue laser resulted in significantly greater localized edema at postoperative visits one and two. At visit three and four, there are no significant differences. VF stiffness following blue laser was 2.41 ± 0.67, 1.91 ± 0.69, 1.33 ± 0.47, and 1.10 ± 0.18 (out of 4) at postoperative visits 1-4, respectively. Postoperative VF stiffness did not differ significantly from KTP laser. Postoperative hemorrhage severity after blue laser was 1.79 ± 0.54, 1.59 ± 0.48, 1.15 ± 0.25, and 1.14 ± 0.26 (out of 4) at postoperative visits 1-4, respectively. Blue laser resulted in significantly less VF hemorrhage than KTP laser at the first (1.79 ± 0.54 versus 2.26 ± 0.83) and second (1.59 ± 0.48 versus 1.98 ± 0.72) postoperative visits. Vascular lesions treated with low-power-density blue laser were significantly more likely to recur than those treated with KTP laser (40.74% versus 10.00%). New vascular malformations were significantly more likely to form after blue laser than KTP (24.07% versus 6.00%). Subjects treated with low-power-density blue laser were significantly more likely to undergo repeat surgery than those treated with KTP (31.48% versus 14.00%). Significant predictors for the need for repeat blue laser included lesion recurrence, a lower surgical objective score at the third or fourth postoperative visit and a higher baseline lesion severity grade. CONCLUSION: Blue laser is an effective tool for the surgical management of VF vascular lesions. Although overall surgical success ratings were inferior to KTP laser at the power densities used, the severity of postoperative edema and VF hemorrhage were significantly less with blue laser. Re-evaluation of blue laser using higher power densities is in progress.